# LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b7643c2c
Ticker: LNSR
Company: LENSAR
Source: LENSAR
Published: 2025-09-02 20:01 EST
## Summary

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the...

## Article Body
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU represents a contingent right to receive one share of the Company’s common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new employee’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a restricted stock unit agreement covering the grant.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
## Recent Company News
- 2026-05-08 11:00 EST — [LENSAR® Reports First Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/LNSR/lensar-reports-first-quarter-2026-results-and-provides-business-update-4b47a128) — Source: LENSAR
- 2026-04-30 11:00 EST — [LENSAR® to Report First Quarter 2026 Results on May 8, 2026](https://biopharmsignal.com/news/LNSR/lensar-to-report-first-quarter-2026-results-on-may-8-2026-05c060f4) — Source: LENSAR
- 2026-03-31 10:00 EST — [LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update](https://biopharmsignal.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-u-37104083) — Source: LENSAR
- 2026-03-16 20:30 EST — [LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC](https://biopharmsignal.com/news/LNSR/lensar-announces-termination-of-merger-agreement-with-alcon-research-llc-329e1882) — Source: LENSAR
- 2026-02-25 22:00 EST — [LENSAR® Provides Update on Pending Acquisition by Alcon](https://biopharmsignal.com/news/LNSR/lensar-provides-update-on-pending-acquisition-by-alcon-a1a49edc) — Source: LENSAR
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)